Immune-inflammatory processes and gene therapeutics

Summary

The Immune-inflammatory Processes and Gene Therapy research group carries out translational research with a primary focus on the molecular basis of immune-inflammatory processes. Its aim is to promote relevant, high-quality research into inflammation and to provide an optimal environment for training young researchers.

88 Publications

Strategic lines

Selected Publications

Serrano,I;Luque,A;Ruiz Cerulla,A;Navas,S;Blom,AM;de Córdoba,SR;Fernández,FJ et al, C4BP(ß-)-mediated immunomodulation attenuates inflammation in DSS-induced murine colitis and in myeloid cells from IBD patients, Pharmacol. Res., 2023;197106948-106948, doi:10.1016/j.phrs.2023.106948,
Serrano I, Luque A, Mitjavila F, Blom AM, Rodríguez de Córdoba S, Vega MC, Torras J, Aran JM. The Hidden Side of Complement Regulator C4BP: Dissection and Evaluation of Its Immunomodulatory Activity. Front. Immunol. 2022;13883743-883743. doi:10.3389/fimmu.2022.883743.
Checa J, Martinez Gonzalez I, Maqueda M, Mosquera JL, Aran JM. Genome-Wide RNAi Screening Identifies Novel Pathways/Genes Involved in Oxidative Stress and Repurposable Drugs to Preserve Cystic Fibrosis Airway Epithelial Cell Integrity. Antioxidants. 2021;10(12):doi:10.3390/antiox10121936.
Hueso M, Mallén A, Suñé Pou M, Aran JM, Suñé Negre JM, Navarro E. ncRNAs in Therapeutics: Challenges and Limitations in Nucleic Acid-Based Drug Delivery. Int J Mol Sci. 2021;22(21):doi:10.3390/ijms222111596.
Guiteras J, Ripoll E, Bolanos N, de Ramon L, Fontova P, Lloberas N, Cruzado JM, Aran JM, Avino A, Eritja R, Goma M, Taco R, Grinyo JM, Torras J. The gene silencing of IRF5 and BLYSS effectively modulates the outcome of experimental lupus nephritis. Mol. Ther. Nucl. Acids. 2021;24807-821. doi:10.1016/j.omtn.2021.03.019.

Selected Projects

FIS23037. Caracterización de Heptammune, un nuevo inmunomodulador biológico para controlar la hiperinflamación y la inmunidad entrenada desadaptada en enfermedades autoinmunes. Instituto de Salud Carlos III (ISCIII). Budget: 252.500€. 2024-2026. PI: ARAN PERRAMON, JOSEP Mª.
21FIS019. Caracterización, potencial diagnóstico y terapeútico de un nuevo inmunomodulador biológico para el tratamiento de enfermedades autoinmunes. Instituto de Salud Carlos III (ISCIII). Budget: 171.820€. 2021-2025. PI: ARAN PERRAMON, JOSEP Mª.
21FIS011. Desarrollo de un nuevo biológico restaurador de la tolerancia inmunitaria. Aplicación al tratamiento de la enfermedad inflamatoria intestinal. Instituto de Salud Carlos III (ISCIII). Budget: 115.500€. 2021-2023. PI: ARAN PERRAMON, JOSEP Mª.
AGA22021. PurPose Biotherapeutics: first-in-class metabolic modulators against autoimmune diseases. AGENCIA GESTIO D'AJUTS UNIV. I RECERCA. Budget: 84.000,06€. 2022-2024. PI: ARAN PERRAMON, JOSEP Mª.
LCX22001. PRP6-HO7: a first-in-class biologic immunomodulator against autoimmune diseases. FUNDACIÓ "LA CAIXA". Budget: 70.000€. 2022-2024. PI: ARAN PERRAMON, JOSEP Mª.

Technology transfer

PAT10- "Compositions and methods for immunomodulation"
IP: Josep Maria Aran
OWNERSHIP:100% IDIBELL
REQUEST No.: EP11382240
PRIORITY COUNTRY: European Union
PRIORITY DATE: 15/07/11
PCT APPLICATION: PCT/EP2012/063932 (16/07/12)

PAT057-Predictive methods of atherosclerosis and stenosis
EP16382025
IP: Josep Maria Aran, Ana Luque

PAT62- "C4BP-based compounds for treating immunological diseases"
OWNERSHIP:100% IDIBELL
REQUEST No.: EP17382187
PRIORITY COUNTRY: European Union
PRIORITY DATE: 06/04/17
PCT APPLICATION: PCT/EP2018/058773 (06/07/18)

PAT76- “Compounds for immunomodulation"
INVENTORS: Aran, J.M., Luque, A., Serrano, I.
OWNERSHIP:100% IDIBELL
REQUEST No.: EP19382910
PRIORITY COUNTRY: European Union
PRIORITY DATE: 17/10/19

License: ISR-TEST: Test ràpid pel diagnòstic del risc d'ICTUS
PI: Dr. Josep Maria Aran